Source comparison
Dosing Protocols: Loading Phase vs Maintenance Phase
The loading phase establishes baseline melanin density before UV exposure begins. Clinical protocols use 0.16–0.25mg/kg daily for 10–14 days. For a 70kg individual, this translates to approximately 250–350mcg daily. Subcutaneous injection in abdominal tissue p
This comparison does not assign a generated winner or score.
- The loading phase establishes baseline melanin density before UV exposure begins. Clinical protocols use 0.16–0.25mg/kg daily for 10–14 days. For a 70kg individual, this translates to approximately 250–350mcg daily. Subcutaneous injection in abdominal tissue provides consistent absorption kinetics; intramuscular administration produces erratic plasma levels due to variable depot release. Reconstituted Melanotan-1 stored at 2–8°C maintains potency for 28 days when using bacteriostatic water. Temperature excursions above 8°C denature the peptide structure irreversibly.
- The maintenance phase begins once baseline eumelanin is established and continues throughout UV exposure periods. Dosing frequency can shift to every other day at the same per-dose amount, or daily dosing can continue at 60–70% of the loading dose. The University of Zurich's dermatology research group found that maintenance dosing at 0.1mg/kg three times weekly sustained elevated MED for the duration of controlled UV therapy in EPP patients, with minimal additional pigmentation beyond the loading phase plateau.
- UV exposure coordination is non-negotiable: melanin synthesis requires UV-induced DNA damage response signaling to proceed beyond the tyrosinase activation step. Patients who dose without UV exposure accumulate inactive melanin precursors that do not confer photoprotection. Controlled UV exposure. Typically 70–80% of individual MED, administered 2–3 times weekly. Triggers the p53-mediated melanogenesis pathway that converts precursors into functional eumelanin deposits. Natural sunlight works, but dose control is critical. Exceeding MED during the loading phase causes erythema that temporarily halts melanin deposition.